PMID- 32548305
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2381-4683 (Electronic)
IS  - 2381-4683 (Linking)
VI  - 5
IP  - 1
DP  - 2020 Jan-Jun
TI  - Non-Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A 
      Discrete Choice Experiment.
PG  - 2381468320922208
LID - 10.1177/2381468320922208 [doi]
LID - 2381468320922208
AB  - Background. There has been much innovation in the treatment of non-small cell 
      lung cancer (NSCLC) in recent years. In particular, use of immuno-oncology (IO) 
      therapies has been growing. Methods. Patients with NSCLC in the United States 
      were surveyed online using a discrete choice experiment to elicit first-line (1L) 
      treatment preferences across six treatment attributes: survival, adverse events 
      (AEs), mechanism of action (MOA), subsequent treatment options (STOs), genetic 
      testing treatment delay, and out-of-pocket cost (OOPC). Preferences were 
      estimated using a latent-class model. Preference shares were estimated for IO-IO, 
      IO-chemo, and chemo-like regimens. Results. Of the 199 patients who completed the 
      survey, 55% were male, 76% were white, 19% had not begun or were on 1L treatment, 
      and the median age was 43 years. Based on a latent-class model with 3 preference 
      classes, 53.0% of patients considered survival and OOPC alone and were less 
      likely to choose an option with a higher OOPC and lower survival, 12.7% of 
      patients were likely to choose the more expensive option, and for 34.3% of 
      patients, survival, AE risk, and treatment delays all significantly influenced 
      choices. MOA and STOs did not significantly influence treatment choices in any 
      preference class. Approximately 53%, 27%, and 20% of patients preferred 
      IO-IO-like, IO-chemo-like, and chemo-like regimens in 1L, respectively. 
      Respondents were younger, more likely to be Caucasian, and more likely to speak 
      English than the general NSCLC patient population. Conclusions. OOPC, 
      effectiveness, treatment delays, and safety influenced NSCLC patients' 1L 
      treatment decisions, and most patients preferred an IO-IO followed by 
      IO-chemo-like regimen in 1L. Cancer treatment decisions are complex and patient 
      preferences are unique; therefore, patients' treatment objectives should be 
      discussed in shared treatment decision making.
CI  - (c) The Author(s) 2020.
FAU - MacEwan, Joanna P
AU  - MacEwan JP
AUID- ORCID: 0000-0003-2702-1170
AD  - PRECISIONheor, Los Angeles, California.
FAU - Gupte-Singh, Komal
AU  - Gupte-Singh K
AD  - Bristol-Myers Squibb, Princeton, New Jersey.
FAU - Zhao, Lauren M
AU  - Zhao LM
AD  - PRECISIONheor, Los Angeles, California.
FAU - Reckamp, Karen L
AU  - Reckamp KL
AD  - City of Hope Comprehensive Cancer Center, Duarte, California.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - MDM Policy Pract
JT  - MDM policy & practice
JID - 101707716
PMC - PMC7249575
OTO - NOTNLM
OT  - NSCLC
OT  - discrete choice experiment
OT  - immune-oncology
OT  - patient preference
COIS- The author(s) declared the following potential conflicts of interest with respect 
      to the research, authorship, and/or publication of this article: Joanna MacEwan 
      and Lauren Zhao are employees of PRECISIONheor, a research consultancy to the 
      health and life science industries. Karen Reckamp is a Scientific Advisor to 
      PRECISIONheor.
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
PMCR- 2020/05/21
CRDT- 2020/06/18 06:00
PHST- 2019/09/12 00:00 [received]
PHST- 2020/02/17 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
PHST- 2020/05/21 00:00 [pmc-release]
AID - 10.1177_2381468320922208 [pii]
AID - 10.1177/2381468320922208 [doi]
PST - epublish
SO  - MDM Policy Pract. 2020 May 21;5(1):2381468320922208. doi: 
      10.1177/2381468320922208. eCollection 2020 Jan-Jun.